BCYC
Bicycle TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Composite grade F from latest DB weights. Momentum 11.6 / Value 57.3
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.2.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
12
Value
57
Sentiment
N/A
Setup hits (3d)
— · Net —
AI TargetsBase - · Bull - · Bear -
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net —
Target $12.78
Why
Momentum12 · Δ7d +6.2
Value57 · Δ7d -0.2
SentimentN/A · Δ7d -
So what
Weak posture. Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
12
40% active weight
Current posture
7d trendSoftening
Δ7d
+6.2
Δ21d
+3.3
Value
57
60% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
+0.0
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 11.6 / Value 57.3
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$293.47M
Beta
1.64
Shares Out
50.27M
P/E (TTM) · Derived
-1.8
P/S (TTM)
16.18
P/FCF (TTM) · Derived
-1.75
Rev YoY
-91.2%
EPS YoY
-1.1%
Gross Margin
+90.7%
Op Margin
-1007.6%
Net Debt
-$611.14M
Current Ratio
12.66
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology

